Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT4406F in NMOSD
NCT04146285Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Sep 2020
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAT4406F in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-Limiting Toxicity at 4 weeks, Maximum Tolerated Dose up to 6 months and 5 more. Started Sep 2020; status: completed.
02
Drugs
BAT4406F
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT04146285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146285.